Worried about low energy, declining strength, or sexual function? Or concerned about your metabolic health and cardiovascular risk? Testosterone testing matters because this hormone drives muscle maintenance, bone density, energy production, and metabolic rate — and it declines with age and metabolic dysfunction. For men, total testosterone reveals hypogonadism and metabolic stress. For women, it flags androgen excess (PCOS, adrenal dysfunction) or deficiency relevant to bone and sexual health.

Testing is particularly valuable if you have a family history of metabolic syndrome, cardiovascular disease, or sexual dysfunction, or if you are experiencing unexplained fatigue, muscle loss, or declining performance. Standard Swedish vårdcentral testing with clinical indication (symptoms + suspicion of hypogonadism) is covered; if total testosterone is borderline, follow-up biomarkers like SHBG and estradiol clarify the picture.

• Identifies hypogonadism early. Catches clinically significant low testosterone before sexual dysfunction or metabolic decline becomes obvious, enabling targeted intervention.

• Reveals metabolic syndrome link. Low testosterone in men is tightly coupled with obesity, insulin resistance, and type 2 diabetes — often the primary driver, not a symptom.

• Guides SHBG and free testosterone interpretation. Total testosterone alone is confounded by SHBG; pairing it with SHBG and free/bioavailable testosterone gives the full picture of androgen bioavailability.

• Predicts cardiovascular risk. Testosterone is strongly associated with lipid profiles, endothelial function, and arterial stiffness — low testosterone correlates with metabolic syndrome and higher cardiovascular events.

• Tracks reproductive and sexual health. Essential for assessing sexual dysfunction, infertility, and reproductive endocrine disorders in both men and women.

• Flags adrenal and endocrine dysfunction. Abnormal total testosterone may signal PCOS, adrenal disease, or primary testicular failure — guides further workup.

Testosterone synthesis and circulation. Testosterone is produced primarily in the Leydig cells of the testes (men) and the ovaries and adrenal cortex (women). Once released, it binds to two main transport proteins: sex hormone-binding globulin (SHBG, which binds ~60–70% of testosterone with very high affinity) and albumin (which binds ~25–30% more loosely). The remaining ~1–2% remains free and unbound — this free testosterone is the only fraction that can enter cells and activate androgen receptors. Total testosterone is the sum of all three fractions.

Why total testosterone matters biologically. Total testosterone drives anabolic processes: muscle protein synthesis, bone mineral density, red blood cell production, and metabolic rate. It also improves endothelial function and lipid metabolism. In the brain, it supports mood, sexual desire, and cognitive function. Low testosterone impairs all of these — muscle wasting accelerates, bone density drops, fat preferentially accumulates around the abdomen, insulin resistance worsens, and cardiovascular risk rises.

The SHBG confounding problem. Total testosterone is heavily confounded by SHBG. High SHBG (due to aging, hyperthyroidism, estrogens, alcohol, hepatitis, or anticonvulsants) binds more testosterone, raising the total without increasing bioavailable testosterone. Conversely, low SHBG (obesity, insulin resistance, hypothyroidism, androgens) lowers total testosterone even if the free fraction is normal. This is why borderline total testosterone requires SHBG measurement and free/bioavailable testosterone calculation to avoid false interpretation.

• Metabolic syndrome is often testosterone-driven. Men with low testosterone have a 2–4 fold higher risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease compared to age-matched controls with normal testosterone. Identifying and addressing low testosterone can interrupt this cascade.

• Hypogonadism has a high cardiovascular burden. Low testosterone is associated with increased arterial stiffness, worse lipid profiles, impaired endothelial function, and higher rates of myocardial infarction and stroke — independent of age and traditional risk factors. This effect is pronounced in men with concurrent metabolic dysfunction.

• Measurement timing and confounders matter clinically. Total testosterone is highest in the morning (7–10 AM) when most men should be tested for diagnostic accuracy. Acute illness, intense exercise within 48 hours, and certain medications (opioids, glucocorticoids) suppress testosterone. Testing under suboptimal conditions leads to false low readings and misdiagnosis.

• Symptomatic hypogonadism thresholds are evidence-based. European guidelines (EMAS, ISSM) define symptomatic hypogonadism as total testosterone < 12 nmol/L in men with clinical symptoms (low libido, erectile dysfunction, fatigue, muscle loss) confirmed on a repeat test. Total T between 12–20 nmol/L is a grey zone — treatment decisions require symptoms, comorbidities, and consultation, not total T number alone.

Testosterone ranges differ markedly by sex and age. Normal ranges are based on healthy population percentiles; optimal longevity ranges account for metabolic health and cardiovascular risk reduction.

• Men — Standard Swedish reference (vårdcentralen): 8–30 nmol/L (age-dependent; 18–40 years typically 12–30 nmol/L, declining ~1% per year thereafter).

• Men — Loovi optimal (longevity and metabolic health): > 15 nmol/L; > 18 nmol/L preferred if metabolically at-risk. Levels 12–15 nmol/L warrant investigation into SHBG, metabolic status, and symptomatology.

• Men — Symptomatic hypogonadism threshold: < 12 nmol/L with clinical symptoms (erectile dysfunction, low libido, fatigue, muscle loss) on repeat testing. Between 12–20 nmol/L, symptoms and comorbidities guide interpretation.

• Women — Standard Swedish reference (vårdcentralen): 0.3–2.0 nmol/L (premenopausal), 0.1–1.5 nmol/L (postmenopausal).

• Women — Loovi optimal (longevity): 0.5–2.0 nmol/L (premenopausal). Below 0.5 nmol/L warrants investigation into adrenal or ovarian dysfunction, especially if sexual function or bone health is affected.

Risk rises sharply below the optimal tier. Men with total testosterone consistently below 12 nmol/L and symptoms of hypogonadism benefit from further evaluation. Women below 0.3 nmol/L with sexual dysfunction or poor bone density also warrant investigation. The gap between standard reference and longevity optimal reflects the strong association between lower-normal testosterone and metabolic dysfunction, cardiovascular events, and quality of life — even within the "normal" range.

Low total testosterone (men < 12 nmol/L with symptoms). Reflects either testicular failure (primary hypogonadism) or pituitary/hypothalamic disease (secondary hypogonadism). Primary hypogonadism shows elevated LH and FSH; secondary shows low or inappropriately low LH/FSH. Metabolic drivers (obesity, insulin resistance, poor sleep, chronic stress) often suppress testosterone secondarily. Check SHBG, LH, FSH, estradiol, and basic metabolic markers (glucose, triglycerides, BMI) to distinguish primary from secondary and guide intervention.

Borderline total testosterone (men 12–20 nmol/L). In a symptom-free man, this is often within normal variation and requires no intervention. In a symptomatic man (erectile dysfunction, fatigue, muscle loss), this requires further evaluation: measure SHBG and calculate free/bioavailable testosterone; assess metabolic parameters (insulin resistance, metabolic syndrome); check LH and FSH to identify testicular vs. pituitary disease. Many men in this range respond to metabolic optimization (weight loss, exercise, sleep) without pharmacological testosterone replacement.

Optimal total testosterone (men > 18 nmol/L). Supports normal metabolic function, cardiovascular health, and sexual and reproductive function. Paired with low SHBG and normal LH/FSH, indicates healthy androgen status.

High total testosterone (men > 30 nmol/L). Rare in naturally-aging men; may reflect external testosterone replacement, anabolic steroid use, or (rarely) testosterone-secreting tumors. In women, elevated testosterone (> 2 nmol/L) suggests PCOS, adrenal hyperplasia, or androgen-secreting tumor — warrants investigation with DHEA-S, LH/FSH ratio, and pelvic imaging if clinically indicated.

Factors that influence testosterone. Measurement timing matters: testosterone peaks 7–10 AM and declines through the day. Fasting status, acute illness, intense exercise within 48 hours, and recent vaccination suppress testosterone. Medications (opioids, glucocorticoids, some anticonvulsants) reduce testosterone; others increase SHBG (estrogens, anticonvulsants, HIV medications) and lower free fraction. Alcohol, obesity, and poor sleep suppress testosterone; sleep deprivation alone can drop levels 10–15%. Menstrual cycle and oral contraceptives (which raise SHBG) strongly affect total testosterone in women.

• Metabolic dysfunction and obesity. Insulin resistance and abdominal obesity suppress testicular testosterone production (secondary hypogonadism) — this is the most common cause of low testosterone in modern men. Leptin resistance and chronic inflammation impair the hypothalamic-pituitary axis. Obesity also increases SHBG-binding capacity, further reducing free testosterone.

• Aging and senescence. Total testosterone declines ~1% per year in healthy men from age 30 onwards, but the rate and magnitude vary widely. Poor metabolic health, chronic disease, and medications accelerate decline. Women's testosterone drops sharply at menopause as ovarian production ceases.

• Genetic polymorphisms and primary testicular dysfunction. Genetic variants in the androgen receptor, 17β-HSD, CYP19A1, and other steroidogenic enzymes affect testosterone synthesis and clearance. Primary testicular disease (Klinefelter, cryptorchidism, radiation, chemotherapy) prevents testosterone production despite normal pituitary signaling.

• Endocrine and metabolic disease. Type 2 diabetes, thyroid disease (hyperthyroidism raises SHBG, hypothyroidism lowers it), prolactinoma, pituitary adenoma, and adrenal insufficiency all disrupt testosterone homeostasis. Chronic inflammation and hepatic disease alter SHBG and testosterone clearance.

• Medications and substances. Opioids, glucocorticoids, 5-alpha-reductase inhibitors, androgen receptor antagonists (for prostate cancer), and some anticonvulsants suppress testosterone. Estrogen-containing oral contraceptives raise SHBG in women; alcohol, cannabis, and anabolic steroid abuse dysregulate the hypothalamic-pituitary axis.

• Metabolic optimization is the primary lever. Weight loss via caloric deficit (especially abdominal fat loss) increases testicular testosterone production and lowers SHBG, raising free testosterone. Insulin resistance drives low testosterone; improving glucose tolerance through reduced refined carbohydrate intake and regular aerobic exercise restores the hypothalamic-pituitary-gonadal axis.

• Resistance training and strength work upregulate testosterone. Progressive resistance exercise stimulates acute testosterone release and enhances receptor sensitivity in muscle tissue. Intensity and volume matter — compound movements (squats, deadlifts, presses) are more potent than isolation work. Consistency over months is needed for sustained improvement.

• Sleep and circadian rhythm alignment. Sleep deprivation acutely suppresses testosterone; chronic poor sleep entrenches low testosterone. Aim for 7–9 hours nightly. Testosterone is synthesized and released primarily at night — poor sleep architecture disrupts this pattern. Morning light exposure and consistent sleep timing stabilize testosterone.

• Nutritional adequacy. Zinc deficiency impairs testosterone synthesis; adequate zinc intake (from meat, shellfish, seeds, legumes) supports testicular function. Vitamin D deficiency is associated with low testosterone; adequate levels (25-OH vitamin D > 75 nmol/L) support androgen production. Excessive polyunsaturated fat intake can suppress testosterone; adequate saturated fat and cholesterol (needed for steroid synthesis) support normal levels. Avoid chronic energy deficit — severe caloric restriction suppresses testosterone acutely.

• Stress management and HPA axis regulation. Chronic psychological stress elevates cortisol, which suppresses GnRH secretion and testosterone synthesis. Regular stress-reducing practices (meditation, movement, social connection) lower cortisol and improve testosterone. Cortisol and testosterone are inversely related, especially under chronic stress.

• Pharmacological approaches (where indicated). Testosterone replacement therapy (TRT) is legitimate and evidence-based treatment for symptomatic hypogonadism with confirmed low testosterone — it restores sexual function, muscle mass, bone density, and mood. However, TRT is not a longevity enhancer or anti-aging intervention in eugonadal men; it carries cardiovascular, hematologic, and prostate risks that require monitoring. GnRH agonists and selective estrogen receptor modulators (SERMs) can stimulate endogenous testosterone in men with secondary hypogonadism; these preserve fertility and are alternatives to TRT when fertility is a concern.

The right intervention depends on the individual's testosterone level, metabolic profile, SHBG status, free/bioavailable testosterone, symptoms, comorbidities, and fertility goals — the landscape is complex and personalized. This is where a longevity doctor's consultation maps the full picture and guides a targeted strategy.

Testing total testosterone alone is clinically incomplete. SHBG confounds interpretation: a borderline total testosterone could reflect low testicular production (genuine hypogonadism) or simply high SHBG (which binds testosterone but leaves bioavailable testosterone normal). Measure SHBG and calculate free or bioavailable testosterone to distinguish these cases.

Similarly, testosterone sits within a broader hormonal and metabolic ecology. Elevated estradiol can suppress testicular testosterone and drive metabolic dysfunction; high cortisol indicates chronic stress that suppresses the hypothalamic-pituitary-gonadal axis; poor glycemic control (high HbA1c, fasting glucose) and metabolic syndrome are both drivers and consequences of low testosterone. A comprehensive assessment pairs total testosterone with SHBG, free/bioavailable testosterone, estradiol, cortisol, HbA1c, and lipid markers (triglycerides, ApoB) to identify the true pathophysiology.

Loovi's comprehensive testing covers 120+ biomarkers annually — testosterone in the full context of your metabolic, cardiovascular, and hormonal status. Paired with unrushed 1-on-1 consultations with a longevity doctor, personalized testing protocols, and an evolving health plan, you get the clarity needed to act. Membership starts from 295 SEK/month and includes drop-in blood tests at 80+ Swedish clinics with results in 3 days, physical performance testing, and unlimited chat — all Friskvårdsbidrag-approved.